Global Recombinant Vaccines Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
LPI (LP Information)' newest research report, the “Recombinant Vaccines Industry Forecast” looks at past sales and reviews total world Recombinant Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Vaccines sales for 2023 through 2029. With Recombinant Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Vaccines.
The global Recombinant Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Vaccines market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Recombinant Vaccines market?
What factors are driving Recombinant Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Vaccines market opportunities vary by end market size?
How does Recombinant Vaccines break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.
LPI (LP Information)' newest research report, the “Recombinant Vaccines Industry Forecast” looks at past sales and reviews total world Recombinant Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Vaccines sales for 2023 through 2029. With Recombinant Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Vaccines.
The global Recombinant Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Vaccines market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Subunit Recombinant Vaccines
- Attenuated Recombinant Vaccines
- Vector Recombinant Vaccines
- Recombinant Human Vaccines
- Animal Recombinant Vaccines
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck & Co., Inc
- Green Cross Corporation
- Pfizer Inc.
- Bayer AG
- Sanofi S A.
- Protein Science Corporation
- GlaxoSmithKline Plc.
- Novartis AG
- Bharat Biotech
What is the 10-year outlook for the global Recombinant Vaccines market?
What factors are driving Recombinant Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Vaccines market opportunities vary by end market size?
How does Recombinant Vaccines break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Vaccines Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Recombinant Vaccines by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Recombinant Vaccines by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Vaccines Segment by Type
2.2.1 Subunit Recombinant Vaccines
2.2.2 Attenuated Recombinant Vaccines
2.2.3 Vector Recombinant Vaccines
2.3 Recombinant Vaccines Sales by Type
2.3.1 Global Recombinant Vaccines Sales Market Share by Type (2018-2023)
2.3.2 Global Recombinant Vaccines Revenue and Market Share by Type (2018-2023)
2.3.3 Global Recombinant Vaccines Sale Price by Type (2018-2023)
2.4 Recombinant Vaccines Segment by Application
2.4.1 Recombinant Human Vaccines
2.4.2 Animal Recombinant Vaccines
2.5 Recombinant Vaccines Sales by Application
2.5.1 Global Recombinant Vaccines Sale Market Share by Application (2018-2023)
2.5.2 Global Recombinant Vaccines Revenue and Market Share by Application (2018-2023)
2.5.3 Global Recombinant Vaccines Sale Price by Application (2018-2023)
3 GLOBAL RECOMBINANT VACCINES BY COMPANY
3.1 Global Recombinant Vaccines Breakdown Data by Company
3.1.1 Global Recombinant Vaccines Annual Sales by Company (2018-2023)
3.1.2 Global Recombinant Vaccines Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Vaccines Annual Revenue by Company (2018-2023)
3.2.1 Global Recombinant Vaccines Revenue by Company (2018-2023)
3.2.2 Global Recombinant Vaccines Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Vaccines Sale Price by Company
3.4 Key Manufacturers Recombinant Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Vaccines Product Location Distribution
3.4.2 Players Recombinant Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RECOMBINANT VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Vaccines Market Size by Geographic Region (2018-2023)
4.1.1 Global Recombinant Vaccines Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Recombinant Vaccines Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Vaccines Market Size by Country/Region (2018-2023)
4.2.1 Global Recombinant Vaccines Annual Sales by Country/Region (2018-2023)
4.2.2 Global Recombinant Vaccines Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Vaccines Sales Growth
4.4 APAC Recombinant Vaccines Sales Growth
4.5 Europe Recombinant Vaccines Sales Growth
4.6 Middle East & Africa Recombinant Vaccines Sales Growth
5 AMERICAS
5.1 Americas Recombinant Vaccines Sales by Country
5.1.1 Americas Recombinant Vaccines Sales by Country (2018-2023)
5.1.2 Americas Recombinant Vaccines Revenue by Country (2018-2023)
5.2 Americas Recombinant Vaccines Sales by Type
5.3 Americas Recombinant Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Vaccines Sales by Region
6.1.1 APAC Recombinant Vaccines Sales by Region (2018-2023)
6.1.2 APAC Recombinant Vaccines Revenue by Region (2018-2023)
6.2 APAC Recombinant Vaccines Sales by Type
6.3 APAC Recombinant Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Vaccines by Country
7.1.1 Europe Recombinant Vaccines Sales by Country (2018-2023)
7.1.2 Europe Recombinant Vaccines Revenue by Country (2018-2023)
7.2 Europe Recombinant Vaccines Sales by Type
7.3 Europe Recombinant Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Vaccines by Country
8.1.1 Middle East & Africa Recombinant Vaccines Sales by Country (2018-2023)
8.1.2 Middle East & Africa Recombinant Vaccines Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Vaccines Sales by Type
8.3 Middle East & Africa Recombinant Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Vaccines
10.3 Manufacturing Process Analysis of Recombinant Vaccines
10.4 Industry Chain Structure of Recombinant Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Vaccines Distributors
11.3 Recombinant Vaccines Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT VACCINES BY GEOGRAPHIC REGION
12.1 Global Recombinant Vaccines Market Size Forecast by Region
12.1.1 Global Recombinant Vaccines Forecast by Region (2024-2029)
12.1.2 Global Recombinant Vaccines Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Vaccines Forecast by Type
12.7 Global Recombinant Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co., Inc
13.1.1 Merck & Co., Inc Company Information
13.1.2 Merck & Co., Inc Recombinant Vaccines Product Portfolios and Specifications
13.1.3 Merck & Co., Inc Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck & Co., Inc Main Business Overview
13.1.5 Merck & Co., Inc Latest Developments
13.2 Green Cross Corporation
13.2.1 Green Cross Corporation Company Information
13.2.2 Green Cross Corporation Recombinant Vaccines Product Portfolios and Specifications
13.2.3 Green Cross Corporation Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Green Cross Corporation Main Business Overview
13.2.5 Green Cross Corporation Latest Developments
13.3 Pfizer Inc.
13.3.1 Pfizer Inc. Company Information
13.3.2 Pfizer Inc. Recombinant Vaccines Product Portfolios and Specifications
13.3.3 Pfizer Inc. Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Pfizer Inc. Main Business Overview
13.3.5 Pfizer Inc. Latest Developments
13.4 Bayer AG
13.4.1 Bayer AG Company Information
13.4.2 Bayer AG Recombinant Vaccines Product Portfolios and Specifications
13.4.3 Bayer AG Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bayer AG Main Business Overview
13.4.5 Bayer AG Latest Developments
13.5 Sanofi S A.
13.5.1 Sanofi S A. Company Information
13.5.2 Sanofi S A. Recombinant Vaccines Product Portfolios and Specifications
13.5.3 Sanofi S A. Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi S A. Main Business Overview
13.5.5 Sanofi S A. Latest Developments
13.6 Protein Science Corporation
13.6.1 Protein Science Corporation Company Information
13.6.2 Protein Science Corporation Recombinant Vaccines Product Portfolios and Specifications
13.6.3 Protein Science Corporation Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Protein Science Corporation Main Business Overview
13.6.5 Protein Science Corporation Latest Developments
13.7 GlaxoSmithKline Plc.
13.7.1 GlaxoSmithKline Plc. Company Information
13.7.2 GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolios and Specifications
13.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 GlaxoSmithKline Plc. Main Business Overview
13.7.5 GlaxoSmithKline Plc. Latest Developments
13.8 Novartis AG
13.8.1 Novartis AG Company Information
13.8.2 Novartis AG Recombinant Vaccines Product Portfolios and Specifications
13.8.3 Novartis AG Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Novartis AG Main Business Overview
13.8.5 Novartis AG Latest Developments
13.9 Bharat Biotech
13.9.1 Bharat Biotech Company Information
13.9.2 Bharat Biotech Recombinant Vaccines Product Portfolios and Specifications
13.9.3 Bharat Biotech Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Bharat Biotech Main Business Overview
13.9.5 Bharat Biotech Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Vaccines Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Recombinant Vaccines by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Recombinant Vaccines by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Vaccines Segment by Type
2.2.1 Subunit Recombinant Vaccines
2.2.2 Attenuated Recombinant Vaccines
2.2.3 Vector Recombinant Vaccines
2.3 Recombinant Vaccines Sales by Type
2.3.1 Global Recombinant Vaccines Sales Market Share by Type (2018-2023)
2.3.2 Global Recombinant Vaccines Revenue and Market Share by Type (2018-2023)
2.3.3 Global Recombinant Vaccines Sale Price by Type (2018-2023)
2.4 Recombinant Vaccines Segment by Application
2.4.1 Recombinant Human Vaccines
2.4.2 Animal Recombinant Vaccines
2.5 Recombinant Vaccines Sales by Application
2.5.1 Global Recombinant Vaccines Sale Market Share by Application (2018-2023)
2.5.2 Global Recombinant Vaccines Revenue and Market Share by Application (2018-2023)
2.5.3 Global Recombinant Vaccines Sale Price by Application (2018-2023)
3 GLOBAL RECOMBINANT VACCINES BY COMPANY
3.1 Global Recombinant Vaccines Breakdown Data by Company
3.1.1 Global Recombinant Vaccines Annual Sales by Company (2018-2023)
3.1.2 Global Recombinant Vaccines Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Vaccines Annual Revenue by Company (2018-2023)
3.2.1 Global Recombinant Vaccines Revenue by Company (2018-2023)
3.2.2 Global Recombinant Vaccines Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Vaccines Sale Price by Company
3.4 Key Manufacturers Recombinant Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Vaccines Product Location Distribution
3.4.2 Players Recombinant Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RECOMBINANT VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Vaccines Market Size by Geographic Region (2018-2023)
4.1.1 Global Recombinant Vaccines Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Recombinant Vaccines Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Vaccines Market Size by Country/Region (2018-2023)
4.2.1 Global Recombinant Vaccines Annual Sales by Country/Region (2018-2023)
4.2.2 Global Recombinant Vaccines Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Vaccines Sales Growth
4.4 APAC Recombinant Vaccines Sales Growth
4.5 Europe Recombinant Vaccines Sales Growth
4.6 Middle East & Africa Recombinant Vaccines Sales Growth
5 AMERICAS
5.1 Americas Recombinant Vaccines Sales by Country
5.1.1 Americas Recombinant Vaccines Sales by Country (2018-2023)
5.1.2 Americas Recombinant Vaccines Revenue by Country (2018-2023)
5.2 Americas Recombinant Vaccines Sales by Type
5.3 Americas Recombinant Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Vaccines Sales by Region
6.1.1 APAC Recombinant Vaccines Sales by Region (2018-2023)
6.1.2 APAC Recombinant Vaccines Revenue by Region (2018-2023)
6.2 APAC Recombinant Vaccines Sales by Type
6.3 APAC Recombinant Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Vaccines by Country
7.1.1 Europe Recombinant Vaccines Sales by Country (2018-2023)
7.1.2 Europe Recombinant Vaccines Revenue by Country (2018-2023)
7.2 Europe Recombinant Vaccines Sales by Type
7.3 Europe Recombinant Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Vaccines by Country
8.1.1 Middle East & Africa Recombinant Vaccines Sales by Country (2018-2023)
8.1.2 Middle East & Africa Recombinant Vaccines Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Vaccines Sales by Type
8.3 Middle East & Africa Recombinant Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Vaccines
10.3 Manufacturing Process Analysis of Recombinant Vaccines
10.4 Industry Chain Structure of Recombinant Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Vaccines Distributors
11.3 Recombinant Vaccines Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT VACCINES BY GEOGRAPHIC REGION
12.1 Global Recombinant Vaccines Market Size Forecast by Region
12.1.1 Global Recombinant Vaccines Forecast by Region (2024-2029)
12.1.2 Global Recombinant Vaccines Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Vaccines Forecast by Type
12.7 Global Recombinant Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co., Inc
13.1.1 Merck & Co., Inc Company Information
13.1.2 Merck & Co., Inc Recombinant Vaccines Product Portfolios and Specifications
13.1.3 Merck & Co., Inc Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck & Co., Inc Main Business Overview
13.1.5 Merck & Co., Inc Latest Developments
13.2 Green Cross Corporation
13.2.1 Green Cross Corporation Company Information
13.2.2 Green Cross Corporation Recombinant Vaccines Product Portfolios and Specifications
13.2.3 Green Cross Corporation Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Green Cross Corporation Main Business Overview
13.2.5 Green Cross Corporation Latest Developments
13.3 Pfizer Inc.
13.3.1 Pfizer Inc. Company Information
13.3.2 Pfizer Inc. Recombinant Vaccines Product Portfolios and Specifications
13.3.3 Pfizer Inc. Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Pfizer Inc. Main Business Overview
13.3.5 Pfizer Inc. Latest Developments
13.4 Bayer AG
13.4.1 Bayer AG Company Information
13.4.2 Bayer AG Recombinant Vaccines Product Portfolios and Specifications
13.4.3 Bayer AG Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bayer AG Main Business Overview
13.4.5 Bayer AG Latest Developments
13.5 Sanofi S A.
13.5.1 Sanofi S A. Company Information
13.5.2 Sanofi S A. Recombinant Vaccines Product Portfolios and Specifications
13.5.3 Sanofi S A. Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi S A. Main Business Overview
13.5.5 Sanofi S A. Latest Developments
13.6 Protein Science Corporation
13.6.1 Protein Science Corporation Company Information
13.6.2 Protein Science Corporation Recombinant Vaccines Product Portfolios and Specifications
13.6.3 Protein Science Corporation Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Protein Science Corporation Main Business Overview
13.6.5 Protein Science Corporation Latest Developments
13.7 GlaxoSmithKline Plc.
13.7.1 GlaxoSmithKline Plc. Company Information
13.7.2 GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolios and Specifications
13.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 GlaxoSmithKline Plc. Main Business Overview
13.7.5 GlaxoSmithKline Plc. Latest Developments
13.8 Novartis AG
13.8.1 Novartis AG Company Information
13.8.2 Novartis AG Recombinant Vaccines Product Portfolios and Specifications
13.8.3 Novartis AG Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Novartis AG Main Business Overview
13.8.5 Novartis AG Latest Developments
13.9 Bharat Biotech
13.9.1 Bharat Biotech Company Information
13.9.2 Bharat Biotech Recombinant Vaccines Product Portfolios and Specifications
13.9.3 Bharat Biotech Recombinant Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Bharat Biotech Main Business Overview
13.9.5 Bharat Biotech Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Recombinant Vaccines Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Vaccines Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Subunit Recombinant Vaccines
Table 4. Major Players of Attenuated Recombinant Vaccines
Table 5. Major Players of Vector Recombinant Vaccines
Table 6. Global Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 7. Global Recombinant Vaccines Sales Market Share by Type (2018-2023)
Table 8. Global Recombinant Vaccines Revenue by Type (2018-2023) & ($ million)
Table 9. Global Recombinant Vaccines Revenue Market Share by Type (2018-2023)
Table 10. Global Recombinant Vaccines Sale Price by Type (2018-2023) & (USD/Unit)
Table 11. Global Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 12. Global Recombinant Vaccines Sales Market Share by Application (2018-2023)
Table 13. Global Recombinant Vaccines Revenue by Application (2018-2023)
Table 14. Global Recombinant Vaccines Revenue Market Share by Application (2018-2023)
Table 15. Global Recombinant Vaccines Sale Price by Application (2018-2023) & (USD/Unit)
Table 16. Global Recombinant Vaccines Sales by Company (2018-2023) & (K Units)
Table 17. Global Recombinant Vaccines Sales Market Share by Company (2018-2023)
Table 18. Global Recombinant Vaccines Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Recombinant Vaccines Revenue Market Share by Company (2018-2023)
Table 20. Global Recombinant Vaccines Sale Price by Company (2018-2023) & (USD/Unit)
Table 21. Key Manufacturers Recombinant Vaccines Producing Area Distribution and Sales Area
Table 22. Players Recombinant Vaccines Products Offered
Table 23. Recombinant Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Recombinant Vaccines Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Recombinant Vaccines Sales Market Share Geographic Region (2018-2023)
Table 28. Global Recombinant Vaccines Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Recombinant Vaccines Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Recombinant Vaccines Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Recombinant Vaccines Sales Market Share by Country/Region (2018-2023)
Table 32. Global Recombinant Vaccines Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Recombinant Vaccines Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Recombinant Vaccines Sales by Country (2018-2023) & (K Units)
Table 35. Americas Recombinant Vaccines Sales Market Share by Country (2018-2023)
Table 36. Americas Recombinant Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Recombinant Vaccines Revenue Market Share by Country (2018-2023)
Table 38. Americas Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 39. Americas Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 40. APAC Recombinant Vaccines Sales by Region (2018-2023) & (K Units)
Table 41. APAC Recombinant Vaccines Sales Market Share by Region (2018-2023)
Table 42. APAC Recombinant Vaccines Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Recombinant Vaccines Revenue Market Share by Region (2018-2023)
Table 44. APAC Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 45. APAC Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 46. Europe Recombinant Vaccines Sales by Country (2018-2023) & (K Units)
Table 47. Europe Recombinant Vaccines Sales Market Share by Country (2018-2023)
Table 48. Europe Recombinant Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Recombinant Vaccines Revenue Market Share by Country (2018-2023)
Table 50. Europe Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 51. Europe Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Recombinant Vaccines Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Recombinant Vaccines Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Recombinant Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Recombinant Vaccines Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Recombinant Vaccines
Table 59. Key Market Challenges & Risks of Recombinant Vaccines
Table 60. Key Industry Trends of Recombinant Vaccines
Table 61. Recombinant Vaccines Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Recombinant Vaccines Distributors List
Table 64. Recombinant Vaccines Customer List
Table 65. Global Recombinant Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Recombinant Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Recombinant Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Recombinant Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Recombinant Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Recombinant Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Recombinant Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Recombinant Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Recombinant Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Recombinant Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Recombinant Vaccines Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Recombinant Vaccines Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Recombinant Vaccines Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Recombinant Vaccines Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Merck & Co., Inc Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck & Co., Inc Recombinant Vaccines Product Portfolios and Specifications
Table 81. Merck & Co., Inc Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 82. Merck & Co., Inc Main Business
Table 83. Merck & Co., Inc Latest Developments
Table 84. Green Cross Corporation Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 85. Green Cross Corporation Recombinant Vaccines Product Portfolios and Specifications
Table 86. Green Cross Corporation Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 87. Green Cross Corporation Main Business
Table 88. Green Cross Corporation Latest Developments
Table 89. Pfizer Inc. Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Inc. Recombinant Vaccines Product Portfolios and Specifications
Table 91. Pfizer Inc. Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 92. Pfizer Inc. Main Business
Table 93. Pfizer Inc. Latest Developments
Table 94. Bayer AG Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 95. Bayer AG Recombinant Vaccines Product Portfolios and Specifications
Table 96. Bayer AG Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 97. Bayer AG Main Business
Table 98. Bayer AG Latest Developments
Table 99. Sanofi S A. Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi S A. Recombinant Vaccines Product Portfolios and Specifications
Table 101. Sanofi S A. Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 102. Sanofi S A. Main Business
Table 103. Sanofi S A. Latest Developments
Table 104. Protein Science Corporation Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 105. Protein Science Corporation Recombinant Vaccines Product Portfolios and Specifications
Table 106. Protein Science Corporation Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 107. Protein Science Corporation Main Business
Table 108. Protein Science Corporation Latest Developments
Table 109. GlaxoSmithKline Plc. Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 110. GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolios and Specifications
Table 111. GlaxoSmithKline Plc. Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 112. GlaxoSmithKline Plc. Main Business
Table 113. GlaxoSmithKline Plc. Latest Developments
Table 114. Novartis AG Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 115. Novartis AG Recombinant Vaccines Product Portfolios and Specifications
Table 116. Novartis AG Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 117. Novartis AG Main Business
Table 118. Novartis AG Latest Developments
Table 119. Bharat Biotech Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 120. Bharat Biotech Recombinant Vaccines Product Portfolios and Specifications
Table 121. Bharat Biotech Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 122. Bharat Biotech Main Business
Table 123. Bharat Biotech Latest Developments
Table 1. Recombinant Vaccines Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Vaccines Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Subunit Recombinant Vaccines
Table 4. Major Players of Attenuated Recombinant Vaccines
Table 5. Major Players of Vector Recombinant Vaccines
Table 6. Global Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 7. Global Recombinant Vaccines Sales Market Share by Type (2018-2023)
Table 8. Global Recombinant Vaccines Revenue by Type (2018-2023) & ($ million)
Table 9. Global Recombinant Vaccines Revenue Market Share by Type (2018-2023)
Table 10. Global Recombinant Vaccines Sale Price by Type (2018-2023) & (USD/Unit)
Table 11. Global Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 12. Global Recombinant Vaccines Sales Market Share by Application (2018-2023)
Table 13. Global Recombinant Vaccines Revenue by Application (2018-2023)
Table 14. Global Recombinant Vaccines Revenue Market Share by Application (2018-2023)
Table 15. Global Recombinant Vaccines Sale Price by Application (2018-2023) & (USD/Unit)
Table 16. Global Recombinant Vaccines Sales by Company (2018-2023) & (K Units)
Table 17. Global Recombinant Vaccines Sales Market Share by Company (2018-2023)
Table 18. Global Recombinant Vaccines Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Recombinant Vaccines Revenue Market Share by Company (2018-2023)
Table 20. Global Recombinant Vaccines Sale Price by Company (2018-2023) & (USD/Unit)
Table 21. Key Manufacturers Recombinant Vaccines Producing Area Distribution and Sales Area
Table 22. Players Recombinant Vaccines Products Offered
Table 23. Recombinant Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Recombinant Vaccines Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Recombinant Vaccines Sales Market Share Geographic Region (2018-2023)
Table 28. Global Recombinant Vaccines Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Recombinant Vaccines Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Recombinant Vaccines Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Recombinant Vaccines Sales Market Share by Country/Region (2018-2023)
Table 32. Global Recombinant Vaccines Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Recombinant Vaccines Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Recombinant Vaccines Sales by Country (2018-2023) & (K Units)
Table 35. Americas Recombinant Vaccines Sales Market Share by Country (2018-2023)
Table 36. Americas Recombinant Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Recombinant Vaccines Revenue Market Share by Country (2018-2023)
Table 38. Americas Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 39. Americas Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 40. APAC Recombinant Vaccines Sales by Region (2018-2023) & (K Units)
Table 41. APAC Recombinant Vaccines Sales Market Share by Region (2018-2023)
Table 42. APAC Recombinant Vaccines Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Recombinant Vaccines Revenue Market Share by Region (2018-2023)
Table 44. APAC Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 45. APAC Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 46. Europe Recombinant Vaccines Sales by Country (2018-2023) & (K Units)
Table 47. Europe Recombinant Vaccines Sales Market Share by Country (2018-2023)
Table 48. Europe Recombinant Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Recombinant Vaccines Revenue Market Share by Country (2018-2023)
Table 50. Europe Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 51. Europe Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Recombinant Vaccines Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Recombinant Vaccines Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Recombinant Vaccines Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Recombinant Vaccines Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Recombinant Vaccines Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Recombinant Vaccines Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Recombinant Vaccines
Table 59. Key Market Challenges & Risks of Recombinant Vaccines
Table 60. Key Industry Trends of Recombinant Vaccines
Table 61. Recombinant Vaccines Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Recombinant Vaccines Distributors List
Table 64. Recombinant Vaccines Customer List
Table 65. Global Recombinant Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Recombinant Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Recombinant Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Recombinant Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Recombinant Vaccines Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Recombinant Vaccines Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Recombinant Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Recombinant Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Recombinant Vaccines Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Recombinant Vaccines Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Recombinant Vaccines Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Recombinant Vaccines Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Recombinant Vaccines Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Recombinant Vaccines Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Merck & Co., Inc Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck & Co., Inc Recombinant Vaccines Product Portfolios and Specifications
Table 81. Merck & Co., Inc Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 82. Merck & Co., Inc Main Business
Table 83. Merck & Co., Inc Latest Developments
Table 84. Green Cross Corporation Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 85. Green Cross Corporation Recombinant Vaccines Product Portfolios and Specifications
Table 86. Green Cross Corporation Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 87. Green Cross Corporation Main Business
Table 88. Green Cross Corporation Latest Developments
Table 89. Pfizer Inc. Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Inc. Recombinant Vaccines Product Portfolios and Specifications
Table 91. Pfizer Inc. Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 92. Pfizer Inc. Main Business
Table 93. Pfizer Inc. Latest Developments
Table 94. Bayer AG Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 95. Bayer AG Recombinant Vaccines Product Portfolios and Specifications
Table 96. Bayer AG Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 97. Bayer AG Main Business
Table 98. Bayer AG Latest Developments
Table 99. Sanofi S A. Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi S A. Recombinant Vaccines Product Portfolios and Specifications
Table 101. Sanofi S A. Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 102. Sanofi S A. Main Business
Table 103. Sanofi S A. Latest Developments
Table 104. Protein Science Corporation Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 105. Protein Science Corporation Recombinant Vaccines Product Portfolios and Specifications
Table 106. Protein Science Corporation Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 107. Protein Science Corporation Main Business
Table 108. Protein Science Corporation Latest Developments
Table 109. GlaxoSmithKline Plc. Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 110. GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolios and Specifications
Table 111. GlaxoSmithKline Plc. Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 112. GlaxoSmithKline Plc. Main Business
Table 113. GlaxoSmithKline Plc. Latest Developments
Table 114. Novartis AG Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 115. Novartis AG Recombinant Vaccines Product Portfolios and Specifications
Table 116. Novartis AG Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 117. Novartis AG Main Business
Table 118. Novartis AG Latest Developments
Table 119. Bharat Biotech Basic Information, Recombinant Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 120. Bharat Biotech Recombinant Vaccines Product Portfolios and Specifications
Table 121. Bharat Biotech Recombinant Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 122. Bharat Biotech Main Business
Table 123. Bharat Biotech Latest Developments
LIST OF FIGURES
Figure 1. Picture of Recombinant Vaccines
Figure 2. Recombinant Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Vaccines Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Vaccines Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Vaccines Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Subunit Recombinant Vaccines
Figure 10. Product Picture of Attenuated Recombinant Vaccines
Figure 11. Product Picture of Vector Recombinant Vaccines
Figure 12. Global Recombinant Vaccines Sales Market Share by Type in 2022
Figure 13. Global Recombinant Vaccines Revenue Market Share by Type (2018-2023)
Figure 14. Recombinant Vaccines Consumed in Recombinant Human Vaccines
Figure 15. Global Recombinant Vaccines Market: Recombinant Human Vaccines (2018-2023) & (K Units)
Figure 16. Recombinant Vaccines Consumed in Animal Recombinant Vaccines
Figure 17. Global Recombinant Vaccines Market: Animal Recombinant Vaccines (2018-2023) & (K Units)
Figure 18. Global Recombinant Vaccines Sales Market Share by Application (2022)
Figure 19. Global Recombinant Vaccines Revenue Market Share by Application in 2022
Figure 20. Recombinant Vaccines Sales Market by Company in 2022 (K Units)
Figure 21. Global Recombinant Vaccines Sales Market Share by Company in 2022
Figure 22. Recombinant Vaccines Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Recombinant Vaccines Revenue Market Share by Company in 2022
Figure 24. Global Recombinant Vaccines Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Recombinant Vaccines Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 27. Americas Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 28. APAC Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 29. APAC Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 30. Europe Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 31. Europe Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 34. Americas Recombinant Vaccines Sales Market Share by Country in 2022
Figure 35. Americas Recombinant Vaccines Revenue Market Share by Country in 2022
Figure 36. Americas Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 37. Americas Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 38. United States Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Recombinant Vaccines Sales Market Share by Region in 2022
Figure 43. APAC Recombinant Vaccines Revenue Market Share by Regions in 2022
Figure 44. APAC Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 45. APAC Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 46. China Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Recombinant Vaccines Sales Market Share by Country in 2022
Figure 54. Europe Recombinant Vaccines Revenue Market Share by Country in 2022
Figure 55. Europe Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 56. Europe Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 57. Germany Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Recombinant Vaccines Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Recombinant Vaccines Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 66. Egypt Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Recombinant Vaccines in 2022
Figure 72. Manufacturing Process Analysis of Recombinant Vaccines
Figure 73. Industry Chain Structure of Recombinant Vaccines
Figure 74. Channels of Distribution
Figure 75. Global Recombinant Vaccines Sales Market Forecast by Region (2024-2029)
Figure 76. Global Recombinant Vaccines Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Recombinant Vaccines Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Recombinant Vaccines Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Recombinant Vaccines Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Recombinant Vaccines Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Recombinant Vaccines
Figure 2. Recombinant Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Vaccines Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Vaccines Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Vaccines Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Subunit Recombinant Vaccines
Figure 10. Product Picture of Attenuated Recombinant Vaccines
Figure 11. Product Picture of Vector Recombinant Vaccines
Figure 12. Global Recombinant Vaccines Sales Market Share by Type in 2022
Figure 13. Global Recombinant Vaccines Revenue Market Share by Type (2018-2023)
Figure 14. Recombinant Vaccines Consumed in Recombinant Human Vaccines
Figure 15. Global Recombinant Vaccines Market: Recombinant Human Vaccines (2018-2023) & (K Units)
Figure 16. Recombinant Vaccines Consumed in Animal Recombinant Vaccines
Figure 17. Global Recombinant Vaccines Market: Animal Recombinant Vaccines (2018-2023) & (K Units)
Figure 18. Global Recombinant Vaccines Sales Market Share by Application (2022)
Figure 19. Global Recombinant Vaccines Revenue Market Share by Application in 2022
Figure 20. Recombinant Vaccines Sales Market by Company in 2022 (K Units)
Figure 21. Global Recombinant Vaccines Sales Market Share by Company in 2022
Figure 22. Recombinant Vaccines Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Recombinant Vaccines Revenue Market Share by Company in 2022
Figure 24. Global Recombinant Vaccines Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Recombinant Vaccines Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 27. Americas Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 28. APAC Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 29. APAC Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 30. Europe Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 31. Europe Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Recombinant Vaccines Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Recombinant Vaccines Revenue 2018-2023 ($ Millions)
Figure 34. Americas Recombinant Vaccines Sales Market Share by Country in 2022
Figure 35. Americas Recombinant Vaccines Revenue Market Share by Country in 2022
Figure 36. Americas Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 37. Americas Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 38. United States Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Recombinant Vaccines Sales Market Share by Region in 2022
Figure 43. APAC Recombinant Vaccines Revenue Market Share by Regions in 2022
Figure 44. APAC Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 45. APAC Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 46. China Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Recombinant Vaccines Sales Market Share by Country in 2022
Figure 54. Europe Recombinant Vaccines Revenue Market Share by Country in 2022
Figure 55. Europe Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 56. Europe Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 57. Germany Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Recombinant Vaccines Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Recombinant Vaccines Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Recombinant Vaccines Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Recombinant Vaccines Sales Market Share by Application (2018-2023)
Figure 66. Egypt Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Recombinant Vaccines Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Recombinant Vaccines in 2022
Figure 72. Manufacturing Process Analysis of Recombinant Vaccines
Figure 73. Industry Chain Structure of Recombinant Vaccines
Figure 74. Channels of Distribution
Figure 75. Global Recombinant Vaccines Sales Market Forecast by Region (2024-2029)
Figure 76. Global Recombinant Vaccines Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Recombinant Vaccines Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Recombinant Vaccines Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Recombinant Vaccines Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Recombinant Vaccines Revenue Market Share Forecast by Application (2024-2029)
